Marseille, France, January 10, 2019, 7:00 AM CET

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows:


May 15, 2019: Publication of revenue for 1Q2019, with management comments.

May 22, 2019: Annual shareholders meeting in Marseille.

September 13, 2019: Publication of financial statements as of June 30, 2019, with management comments.

November 13, 2019: Publication of revenue for 3Q2019, with management comments.

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (http://www.innate-pharma.com/en/investors/)

About Innate Pharma:

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in-class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:

ISIN code               FR0010331421
Ticker code             IPH
LEI                    9695002Y8420ZB8HJE29

Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

**Investors**

Innate Pharma
Dr. Markus Metzger / Danielle Spangler / Jérôme Marino
Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com

**International Media**

Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com

**French Media**

ATCG Press
Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com